BR9917001A - Conversão de compostos de inibição de cox quenão são inibidores seletivos de cox-2 em derivadosque são inibidores seletivos de cox-2 - Google Patents

Conversão de compostos de inibição de cox quenão são inibidores seletivos de cox-2 em derivadosque são inibidores seletivos de cox-2

Info

Publication number
BR9917001A
BR9917001A BR9917001-9A BR9917001A BR9917001A BR 9917001 A BR9917001 A BR 9917001A BR 9917001 A BR9917001 A BR 9917001A BR 9917001 A BR9917001 A BR 9917001A
Authority
BR
Brazil
Prior art keywords
inhibitors
cox
derivatives
selective cox
selective
Prior art date
Application number
BR9917001-9A
Other languages
English (en)
Inventor
Amit S Kalgutkar
Lawrence J Marnett
Original Assignee
Univ Vanderbilt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Vanderbilt filed Critical Univ Vanderbilt
Publication of BR9917001A publication Critical patent/BR9917001A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Patente de Invenção: "CONVERSãO DE COMPOSTOS DEINIBIçãO DE COX QUE NãO SãO INIBIDORES SELETIVOS DECOX-2 EM DERIVADOS QUE SãO INIBIDORES SELETIVOS DECOX-2". Conversão de compostos de inibição de COX que nãosão inibidores seletivos de COX-2 em derivados que são inibidoresseletivos de COX-2. Um método de alteração de especificidade decompostos de inibição de ciclooxigenase que têm uma porção deCOOH por mudança dos vários compostos contendo COOH, talcomo indometacina, em derivados de éster ou em derivados deamida secundária.
BR9917001-9A 1999-01-07 1999-12-16 Conversão de compostos de inibição de cox quenão são inibidores seletivos de cox-2 em derivadosque são inibidores seletivos de cox-2 BR9917001A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11509099P 1999-01-07 1999-01-07
PCT/US1999/030219 WO2000040087A1 (en) 1999-01-07 1999-12-16 Converting cox inhibition compounds that are not cox-2 selective inhibitors to derivatives that are cox-2 selective inhibitors

Publications (1)

Publication Number Publication Date
BR9917001A true BR9917001A (pt) 2001-11-13

Family

ID=22359275

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9917001-9A BR9917001A (pt) 1999-01-07 1999-12-16 Conversão de compostos de inibição de cox quenão são inibidores seletivos de cox-2 em derivadosque são inibidores seletivos de cox-2

Country Status (11)

Country Link
EP (1) EP1148783B1 (pt)
JP (1) JP2002534361A (pt)
CN (1) CN1227008C (pt)
AT (1) ATE328593T1 (pt)
AU (1) AU772705B2 (pt)
BR (1) BR9917001A (pt)
CA (1) CA2358241A1 (pt)
DE (1) DE69931814T2 (pt)
ES (1) ES2270634T3 (pt)
IL (1) IL144126A0 (pt)
WO (1) WO2000040087A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR030346A1 (es) 2000-08-14 2003-08-20 Alcon Inc Metodo de tratamiento de desordenes neurodegenerativos de la retina y cabeza de nervio optico
AU2002247284A1 (en) 2001-04-02 2002-10-15 Alcon, Inc. Method of treating ocular inflammatory and angiogenesis-related disorders using an amide derivative of flubiprofen or ketorolac
FR2835433B1 (fr) * 2002-02-01 2006-02-17 Richard Lab M Utilisation de la 1-(-4-chlorobenzoyl)-5methoxy-2-methyl-1h- indole-3acetic 4-(acetylamino)phenylester pour la fabrication d'un medicament destine a inhiber exclusivement la cox2
EP1534305B9 (en) 2003-05-07 2007-03-07 Osteologix A/S Treating cartilage / bone conditions with water-soluble strontium salts
JP2007527397A (ja) * 2003-07-01 2007-09-27 マイクロバイア インコーポレイテッド Ｃｏｘ−２及びｆａａｈ阻害剤
JP2007534702A (ja) 2004-04-26 2007-11-29 バンダービルト・ユニバーシティ 胃腸毒性の低い治療薬としてのインドール酢酸、及びインデン酢酸誘導体
CN101528222A (zh) 2006-06-19 2009-09-09 范德比尔特大学 用于诊断性和治疗性靶向cox-2的方法和组合物
CA3209491A1 (en) 2021-03-15 2022-09-22 Saul Yedgar Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3285908A (en) * 1963-04-30 1966-11-15 Merck & Co Inc Indolyl acid amides
US3336194A (en) * 1963-04-30 1967-08-15 Merck & Co Inc Indolyl acid amides
FR2358145A1 (fr) 1976-03-29 1978-02-10 Richard Sa Laboratoire M Nouveau medicament anti-inflammatoire, analgesique et antipyretique a base de (p-chlorobenzoyl-1 methyl-2 methoxy-5)-indole-3 acetate de p-acetamidophenol
JPS5872560A (ja) * 1981-10-27 1983-04-30 Teikoku Chem Ind Corp Ltd インドメタシンフエニルエステル誘導体
JPS60152462A (ja) * 1984-01-20 1985-08-10 Terumo Corp インド−ル酢酸アミド誘導体の製造方法
US5510368A (en) * 1995-05-22 1996-04-23 Merck Frosst Canada, Inc. N-benzyl-3-indoleacetic acids as antiinflammatory drugs

Also Published As

Publication number Publication date
DE69931814D1 (de) 2006-07-20
EP1148783A4 (en) 2003-05-21
AU2369700A (en) 2000-07-24
EP1148783A1 (en) 2001-10-31
ATE328593T1 (de) 2006-06-15
AU772705B2 (en) 2004-05-06
DE69931814T2 (de) 2007-01-04
CN1337851A (zh) 2002-02-27
IL144126A0 (en) 2002-05-23
JP2002534361A (ja) 2002-10-15
EP1148783B1 (en) 2006-06-07
CA2358241A1 (en) 2000-07-13
WO2000040087A1 (en) 2000-07-13
CN1227008C (zh) 2005-11-16
ES2270634T3 (es) 2007-04-01

Similar Documents

Publication Publication Date Title
NO971684D0 (no) Nye benzoxazoler
ES2182234T3 (es) Inhibidores de metaloproteasa.
GB0100889D0 (en) Compounds
CY1110064T1 (el) Παραγωγα φαινυλ-πιπεραζινης ως αναστολεις επαναπροσληψης σεροτονινης
DE69912581D1 (de) Biarylessigsäure-derivate und ihre verwendung als cox-2 inhibitoren
ATE217865T1 (de) Verbindungen zur hemmung von phosphodiesrerase iv
NO20024614L (no) N-heterosykliske derivater som NOS-hemmere
NO20025525D0 (no) Substituerte pyrrolpyridinonderivater, brukbare som fosfordiesterase-inhibitorer
DE60019347D1 (de) Inhibitoren der alpha-l beta-2 vermittelten zelladhäsion
NO20061317L (no) Imidazopyridinderivater som induserbare NO-syntaseinhibatorer
EA200000826A1 (ru) Галоидированные производные амидиноаминокислот, применимые в качестве ингибиторов no-синтазы
ATE438398T1 (de) Pyrrolo-dihydroisochinolin-derivate als pde10- inhibitoren
SE0103710D0 (sv) Compounds
DK1228073T3 (da) Imidazolforbindelser som phosphodiesterase VII-inhibitorer
BR9917001A (pt) Conversão de compostos de inibição de cox quenão são inibidores seletivos de cox-2 em derivadosque são inibidores seletivos de cox-2
NO20061344L (no) Imidazopyridinderivater som induserbare NO-syntaseoinhibitorer
TR200001452T2 (tr) Bifenilamidin türevleri.
EA200100854A1 (ru) Кальций-литические соединения
ATE288922T1 (de) Bestimmte heteroaryl substituierte thiol inhibitoren von endothelin wechselnden enzymen
MY128164A (en) Compounds
DK0656001T3 (da) Nye 2-substituerede indan-2-mercaptoacetylamid-tricycliske derivater til anvendelse som enkefalinasehæmmere
BR0115996A (pt) Sulfamidotienopirimidinas
NO20015892L (no) Inhibitorer av metallproteinaser
DK1324760T3 (da) Creatin-esterholdige pronæringsstoforbindelser og formuleringer
AP2001002045A0 (en) FKBP inhibitors.

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements